HOMER2 study
Hepatocellular carcinoma (HCC) incidence is increasing in Australia and is associated with high mortality. However, there is limited data on the epidemiology of liver cancer in Australia, including the impact.
Objective
The project aims to:
- describe trends in HCC incidence and aetiology over time in Victoria
- describe trends in mortality rates for HCC over time
- determine factors associated with survival, including health services utilization and enrolment in liver cancer surveillance
- describe the impact of marginalization on HCC stage at diagnosis, treatment uptake and clinical outcomes
Timeline
2012–2025.
Approach
Prospective cohort study with data linkage.
Community impact
Understanding the rapidly changing trends in the epidemiology of HCC in Victoria is essential to design effective prevention programs.
Treatment approaches to HCC are changing rapidly.
This study will provide evidence for factors that are associated with improved survival outcomes to inform cost-effectiveness modelling.
Partners
Funding partners
- NHMRC Program grant
- Ramsay Program grant
- Gilead Sciences
- Eisai Australia
Collaborators
- Melbourne Liver Group
- St Vincent’s Hospital Melbourne
- Western Health
- Northern Health
- Eastern Health
- Melbourne Health
- Alfred Health
- Austin Health
- Monash Health
Project contacts
Associate Professor Jessica Howell
Co-head, Hepatitis B and Liver Cancer; Senior Research Fellow
Project team
Dr Michael Curtis
Postdoctoral Research Officer